Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.

Cesare Gridelli, Filippo de Marinis, Andrea Ardizzoni, Silvia Novello, Gabriella Fontanini, Federico Cappuzzo, Francesco Grossi, Antonio Santo, Diego Cortinovis, Adolfo Favaretto, Vito Lorusso, Domenico Galetta, Salvatore Siena, Anna Bettini, Monica Iurlaro, Alberto Caprioli, study team LIFE study team

Research output: Contribution to journalArticle

Abstract

LIFE (non-small cell Lung cancer management In patients progressing after First-linE of treatment in the metastatic setting) is a multicentre Italian observational study, including a cross-sectional and a longitudinal phase, with the aim of describing the therapeutic approach in clinical practice for advanced non-small cell lung cancer (NSCLC) patients, progressing after first-line treatment. In this paper, the cross-sectional phase is outlined, with the primary endpoint of describing the proportion of patients receiving second-line treatment among those progressed during or after first-line treatment according to clinical practice. From July 2011 to January 2012, 603 patients were enrolled and 541 (90 %) were evaluable. A total of 464 (86 %) patients received a second-line therapy outside clinical trials. Chemotherapy and targeted therapies were administered to 65 and 34 % of patients, respectively (1 % both). No tissue collection was required within the observational trial, and biomarkers analysis was performed at diagnosis or later in 314 patients (58 %). In details, activating epidermal growth factor receptor mutations were detected in 21 % of 311 evaluable patients, Kirsten rat sarcoma 2 viral oncogene homolog mutation in 22 % of the 77 evaluable patients and anaplastic lymphoma kinase translocations analysis was performed in 74 patients and resulted positive in 23 % of cases. These high proportions were probably due to enriched patient population tested. These results showed a pattern of care for NSCLC second-line therapy which reflects international guidelines recommendations and current expected clinical practice. Interestingly, biomarkers analyses were performed in a higher percentage than expected.

Original languageEnglish
Pages (from-to)1783-1793
Number of pages11
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number10
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.'. Together they form a unique fingerprint.

  • Cite this

    Gridelli, C., de Marinis, F., Ardizzoni, A., Novello, S., Fontanini, G., Cappuzzo, F., Grossi, F., Santo, A., Cortinovis, D., Favaretto, A., Lorusso, V., Galetta, D., Siena, S., Bettini, A., Iurlaro, M., Caprioli, A., & LIFE study team, S. T. (2014). Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Journal of Cancer Research and Clinical Oncology, 140(10), 1783-1793. https://doi.org/10.1007/s00432-014-1715-2